Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial
Upper airway cough syndrome (UACS) is a common cause of chronic cough characterized by upper airway symptoms, including nasal discharge and throat discomfort. Empirical treatments for UASC-induced chronic cough, such as first-generation antihistamines, have been used; however, the long-term use of t...
Gespeichert in:
Veröffentlicht in: | Healthcare (Basel) 2023-10, Vol.11 (20), p.2733 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 20 |
container_start_page | 2733 |
container_title | Healthcare (Basel) |
container_volume | 11 |
creator | Woo, Seong-Cheon Lyu, Yee Ran Lee, Su Won Kwon, O-Jin Choi, Young-Eun Yang, Changsop Park, Yang Chun |
description | Upper airway cough syndrome (UACS) is a common cause of chronic cough characterized by upper airway symptoms, including nasal discharge and throat discomfort. Empirical treatments for UASC-induced chronic cough, such as first-generation antihistamines, have been used; however, the long-term use of these medicines has adverse effects. Therefore, we evaluate the efficacy, safety, and economic feasibility of Wolbigachul-tang (WBGCT), an herbal medication for UASC-induced chronic cough. This is a randomized, double-blind, active-comparator-controlled, parallel, and exploratory clinical trial. Thirty patients with UASC-induced chronic cough will be recruited and randomly allocated to the WBGCT and control groups in a 1:1 allocation ratio. The investigational medicine will be administered three times per day for 2 weeks (3 g of WBGCT at a time). The primary outcome measure is the cough symptom score measured at screening, before starting the trial, and after 2 and 4 weeks. Secondary outcome measures include the cough visual analog scale, nasal discharge score, questionnaire of clinical symptoms of cough and sputum, Leicester cough questionnaire-Korean version, integrative medicine outcome scale, integrative medicine patient satisfaction scale, and 5-level EuroQol 5-dimensional questionnaire, which will be assessed before starting the trial and after 2 and 4 weeks. This study aims to investigate the efficacy, safety, and economic feasibility of WBGCT in the treatment of chronic cough. Therefore, the results of this trial provide evidence for the application of WBGCT in the treatment of UACS-induced chronic cough. |
doi_str_mv | 10.3390/healthcare11202733 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10606134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A772063956</galeid><sourcerecordid>A772063956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-bbec7807f00c5eb1dfb410f5a8d320e201d2a1e5c08c09ac8d7adee3468702d03</originalsourceid><addsrcrecordid>eNptkttu1DAQhiMEolXpC3BliZsibYpj58gNCulykCpRsVtxGTn2ZOPK60mdZCG8Mi-Bt10BBewLn775f489QfA8ouecF_RVB8KMnRQOoohRlnH-KDhmjGVhQTl7_Mf8KDgdhhvqWxHxnCdPgyOe5QXPaXYc_Fi2rZZCzguyEi2MMxFWkaVEi1styXInzCRGjZZgS76gafRGyG4y4VrYDWnRkapzaD1a4bTpyMUEZERy3ffgSKndVzEfTlazVQ63QM6uy2r18jUpyWqc1EyuHI4o0dypffb23vk7qAW5wKkxEL412vpVKUe9g7DCbS-cGPfOaEeHxuzZK7_nZ2ZBlt96g3eAd_ahPjtD1k4L8yx40gozwOlhPAmu3y3X1Yfw8tP7j1V5GcqYpWPYNCAz_zgtpTKBJlJtE0e0TUSuOKPAaKSYiCCRNJe0EDJXmVAAPE7zjDJF-Unw5l63n5otKAn-msLUvdNb4eYaha4fnljd1Rvc1RFNaRrx2CucHRQc3k4wjPVWDxKMERZwGmqW-3_MkjjhHn3xF3qDk7M-vz3FYhZHcfyb2ggDtbYtemO5F63LLGM05UWSeur8P5TvCnwxoIVW-_0HAew-QDocBgftryQjWu_LtP63TPlPDdjeLA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2882424144</pqid></control><display><type>article</type><title>Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Woo, Seong-Cheon ; Lyu, Yee Ran ; Lee, Su Won ; Kwon, O-Jin ; Choi, Young-Eun ; Yang, Changsop ; Park, Yang Chun</creator><creatorcontrib>Woo, Seong-Cheon ; Lyu, Yee Ran ; Lee, Su Won ; Kwon, O-Jin ; Choi, Young-Eun ; Yang, Changsop ; Park, Yang Chun</creatorcontrib><description>Upper airway cough syndrome (UACS) is a common cause of chronic cough characterized by upper airway symptoms, including nasal discharge and throat discomfort. Empirical treatments for UASC-induced chronic cough, such as first-generation antihistamines, have been used; however, the long-term use of these medicines has adverse effects. Therefore, we evaluate the efficacy, safety, and economic feasibility of Wolbigachul-tang (WBGCT), an herbal medication for UASC-induced chronic cough. This is a randomized, double-blind, active-comparator-controlled, parallel, and exploratory clinical trial. Thirty patients with UASC-induced chronic cough will be recruited and randomly allocated to the WBGCT and control groups in a 1:1 allocation ratio. The investigational medicine will be administered three times per day for 2 weeks (3 g of WBGCT at a time). The primary outcome measure is the cough symptom score measured at screening, before starting the trial, and after 2 and 4 weeks. Secondary outcome measures include the cough visual analog scale, nasal discharge score, questionnaire of clinical symptoms of cough and sputum, Leicester cough questionnaire-Korean version, integrative medicine outcome scale, integrative medicine patient satisfaction scale, and 5-level EuroQol 5-dimensional questionnaire, which will be assessed before starting the trial and after 2 and 4 weeks. This study aims to investigate the efficacy, safety, and economic feasibility of WBGCT in the treatment of chronic cough. Therefore, the results of this trial provide evidence for the application of WBGCT in the treatment of UACS-induced chronic cough.</description><identifier>ISSN: 2227-9032</identifier><identifier>EISSN: 2227-9032</identifier><identifier>DOI: 10.3390/healthcare11202733</identifier><identifier>PMID: 37893807</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Antihistamines ; Asthma ; Blood pressure ; Care and treatment ; Clinical trials ; Cough ; Diagnosis ; Double-blind studies ; Economic aspects ; Evaluation ; Gastroesophageal reflux ; Hay fever ; Histamine ; Medical research ; Medicine, Botanic ; Medicine, Experimental ; Medicine, Herbal ; Participation ; Patient satisfaction ; Respiratory diseases ; Rhinitis ; Safety and security measures ; Sinusitis ; Study Protocol ; Womens health</subject><ispartof>Healthcare (Basel), 2023-10, Vol.11 (20), p.2733</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-bbec7807f00c5eb1dfb410f5a8d320e201d2a1e5c08c09ac8d7adee3468702d03</cites><orcidid>0000-0002-7349-4596 ; 0000-0002-5645-869X ; 0000-0003-1277-3329 ; 0000-0002-1403-5525 ; 0000-0001-6915-3716</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606134/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606134/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Woo, Seong-Cheon</creatorcontrib><creatorcontrib>Lyu, Yee Ran</creatorcontrib><creatorcontrib>Lee, Su Won</creatorcontrib><creatorcontrib>Kwon, O-Jin</creatorcontrib><creatorcontrib>Choi, Young-Eun</creatorcontrib><creatorcontrib>Yang, Changsop</creatorcontrib><creatorcontrib>Park, Yang Chun</creatorcontrib><title>Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial</title><title>Healthcare (Basel)</title><description>Upper airway cough syndrome (UACS) is a common cause of chronic cough characterized by upper airway symptoms, including nasal discharge and throat discomfort. Empirical treatments for UASC-induced chronic cough, such as first-generation antihistamines, have been used; however, the long-term use of these medicines has adverse effects. Therefore, we evaluate the efficacy, safety, and economic feasibility of Wolbigachul-tang (WBGCT), an herbal medication for UASC-induced chronic cough. This is a randomized, double-blind, active-comparator-controlled, parallel, and exploratory clinical trial. Thirty patients with UASC-induced chronic cough will be recruited and randomly allocated to the WBGCT and control groups in a 1:1 allocation ratio. The investigational medicine will be administered three times per day for 2 weeks (3 g of WBGCT at a time). The primary outcome measure is the cough symptom score measured at screening, before starting the trial, and after 2 and 4 weeks. Secondary outcome measures include the cough visual analog scale, nasal discharge score, questionnaire of clinical symptoms of cough and sputum, Leicester cough questionnaire-Korean version, integrative medicine outcome scale, integrative medicine patient satisfaction scale, and 5-level EuroQol 5-dimensional questionnaire, which will be assessed before starting the trial and after 2 and 4 weeks. This study aims to investigate the efficacy, safety, and economic feasibility of WBGCT in the treatment of chronic cough. Therefore, the results of this trial provide evidence for the application of WBGCT in the treatment of UACS-induced chronic cough.</description><subject>Antihistamines</subject><subject>Asthma</subject><subject>Blood pressure</subject><subject>Care and treatment</subject><subject>Clinical trials</subject><subject>Cough</subject><subject>Diagnosis</subject><subject>Double-blind studies</subject><subject>Economic aspects</subject><subject>Evaluation</subject><subject>Gastroesophageal reflux</subject><subject>Hay fever</subject><subject>Histamine</subject><subject>Medical research</subject><subject>Medicine, Botanic</subject><subject>Medicine, Experimental</subject><subject>Medicine, Herbal</subject><subject>Participation</subject><subject>Patient satisfaction</subject><subject>Respiratory diseases</subject><subject>Rhinitis</subject><subject>Safety and security measures</subject><subject>Sinusitis</subject><subject>Study Protocol</subject><subject>Womens health</subject><issn>2227-9032</issn><issn>2227-9032</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkttu1DAQhiMEolXpC3BliZsibYpj58gNCulykCpRsVtxGTn2ZOPK60mdZCG8Mi-Bt10BBewLn775f489QfA8ouecF_RVB8KMnRQOoohRlnH-KDhmjGVhQTl7_Mf8KDgdhhvqWxHxnCdPgyOe5QXPaXYc_Fi2rZZCzguyEi2MMxFWkaVEi1styXInzCRGjZZgS76gafRGyG4y4VrYDWnRkapzaD1a4bTpyMUEZERy3ffgSKndVzEfTlazVQ63QM6uy2r18jUpyWqc1EyuHI4o0dypffb23vk7qAW5wKkxEL412vpVKUe9g7DCbS-cGPfOaEeHxuzZK7_nZ2ZBlt96g3eAd_ahPjtD1k4L8yx40gozwOlhPAmu3y3X1Yfw8tP7j1V5GcqYpWPYNCAz_zgtpTKBJlJtE0e0TUSuOKPAaKSYiCCRNJe0EDJXmVAAPE7zjDJF-Unw5l63n5otKAn-msLUvdNb4eYaha4fnljd1Rvc1RFNaRrx2CucHRQc3k4wjPVWDxKMERZwGmqW-3_MkjjhHn3xF3qDk7M-vz3FYhZHcfyb2ggDtbYtemO5F63LLGM05UWSeur8P5TvCnwxoIVW-_0HAew-QDocBgftryQjWu_LtP63TPlPDdjeLA</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Woo, Seong-Cheon</creator><creator>Lyu, Yee Ran</creator><creator>Lee, Su Won</creator><creator>Kwon, O-Jin</creator><creator>Choi, Young-Eun</creator><creator>Yang, Changsop</creator><creator>Park, Yang Chun</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7349-4596</orcidid><orcidid>https://orcid.org/0000-0002-5645-869X</orcidid><orcidid>https://orcid.org/0000-0003-1277-3329</orcidid><orcidid>https://orcid.org/0000-0002-1403-5525</orcidid><orcidid>https://orcid.org/0000-0001-6915-3716</orcidid></search><sort><creationdate>20231001</creationdate><title>Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial</title><author>Woo, Seong-Cheon ; Lyu, Yee Ran ; Lee, Su Won ; Kwon, O-Jin ; Choi, Young-Eun ; Yang, Changsop ; Park, Yang Chun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-bbec7807f00c5eb1dfb410f5a8d320e201d2a1e5c08c09ac8d7adee3468702d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antihistamines</topic><topic>Asthma</topic><topic>Blood pressure</topic><topic>Care and treatment</topic><topic>Clinical trials</topic><topic>Cough</topic><topic>Diagnosis</topic><topic>Double-blind studies</topic><topic>Economic aspects</topic><topic>Evaluation</topic><topic>Gastroesophageal reflux</topic><topic>Hay fever</topic><topic>Histamine</topic><topic>Medical research</topic><topic>Medicine, Botanic</topic><topic>Medicine, Experimental</topic><topic>Medicine, Herbal</topic><topic>Participation</topic><topic>Patient satisfaction</topic><topic>Respiratory diseases</topic><topic>Rhinitis</topic><topic>Safety and security measures</topic><topic>Sinusitis</topic><topic>Study Protocol</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Woo, Seong-Cheon</creatorcontrib><creatorcontrib>Lyu, Yee Ran</creatorcontrib><creatorcontrib>Lee, Su Won</creatorcontrib><creatorcontrib>Kwon, O-Jin</creatorcontrib><creatorcontrib>Choi, Young-Eun</creatorcontrib><creatorcontrib>Yang, Changsop</creatorcontrib><creatorcontrib>Park, Yang Chun</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Healthcare (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Woo, Seong-Cheon</au><au>Lyu, Yee Ran</au><au>Lee, Su Won</au><au>Kwon, O-Jin</au><au>Choi, Young-Eun</au><au>Yang, Changsop</au><au>Park, Yang Chun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial</atitle><jtitle>Healthcare (Basel)</jtitle><date>2023-10-01</date><risdate>2023</risdate><volume>11</volume><issue>20</issue><spage>2733</spage><pages>2733-</pages><issn>2227-9032</issn><eissn>2227-9032</eissn><abstract>Upper airway cough syndrome (UACS) is a common cause of chronic cough characterized by upper airway symptoms, including nasal discharge and throat discomfort. Empirical treatments for UASC-induced chronic cough, such as first-generation antihistamines, have been used; however, the long-term use of these medicines has adverse effects. Therefore, we evaluate the efficacy, safety, and economic feasibility of Wolbigachul-tang (WBGCT), an herbal medication for UASC-induced chronic cough. This is a randomized, double-blind, active-comparator-controlled, parallel, and exploratory clinical trial. Thirty patients with UASC-induced chronic cough will be recruited and randomly allocated to the WBGCT and control groups in a 1:1 allocation ratio. The investigational medicine will be administered three times per day for 2 weeks (3 g of WBGCT at a time). The primary outcome measure is the cough symptom score measured at screening, before starting the trial, and after 2 and 4 weeks. Secondary outcome measures include the cough visual analog scale, nasal discharge score, questionnaire of clinical symptoms of cough and sputum, Leicester cough questionnaire-Korean version, integrative medicine outcome scale, integrative medicine patient satisfaction scale, and 5-level EuroQol 5-dimensional questionnaire, which will be assessed before starting the trial and after 2 and 4 weeks. This study aims to investigate the efficacy, safety, and economic feasibility of WBGCT in the treatment of chronic cough. Therefore, the results of this trial provide evidence for the application of WBGCT in the treatment of UACS-induced chronic cough.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>37893807</pmid><doi>10.3390/healthcare11202733</doi><orcidid>https://orcid.org/0000-0002-7349-4596</orcidid><orcidid>https://orcid.org/0000-0002-5645-869X</orcidid><orcidid>https://orcid.org/0000-0003-1277-3329</orcidid><orcidid>https://orcid.org/0000-0002-1403-5525</orcidid><orcidid>https://orcid.org/0000-0001-6915-3716</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2227-9032 |
ispartof | Healthcare (Basel), 2023-10, Vol.11 (20), p.2733 |
issn | 2227-9032 2227-9032 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10606134 |
source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
subjects | Antihistamines Asthma Blood pressure Care and treatment Clinical trials Cough Diagnosis Double-blind studies Economic aspects Evaluation Gastroesophageal reflux Hay fever Histamine Medical research Medicine, Botanic Medicine, Experimental Medicine, Herbal Participation Patient satisfaction Respiratory diseases Rhinitis Safety and security measures Sinusitis Study Protocol Womens health |
title | Efficacy, Safety and Economic Evaluation of Wolbigachul-Tang for Chronic Cough Due to Upper Airway Cough Syndrome (UACS): A Study Protocol for Randomized, Double-Blind, Active-Comparator Controlled, Parallel, Exploratory Clinical Trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T20%3A46%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy,%20Safety%20and%20Economic%20Evaluation%20of%20Wolbigachul-Tang%20for%20Chronic%20Cough%20Due%20to%20Upper%20Airway%20Cough%20Syndrome%20(UACS):%20A%20Study%20Protocol%20for%20Randomized,%20Double-Blind,%20Active-Comparator%20Controlled,%20Parallel,%20Exploratory%20Clinical%20Trial&rft.jtitle=Healthcare%20(Basel)&rft.au=Woo,%20Seong-Cheon&rft.date=2023-10-01&rft.volume=11&rft.issue=20&rft.spage=2733&rft.pages=2733-&rft.issn=2227-9032&rft.eissn=2227-9032&rft_id=info:doi/10.3390/healthcare11202733&rft_dat=%3Cgale_pubme%3EA772063956%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2882424144&rft_id=info:pmid/37893807&rft_galeid=A772063956&rfr_iscdi=true |